CoStar: Pivotal trial additional data

Twelve-month follow-up data from the first-arm of the 2-arm, dose-ranging European EuroSTAR trial showed that MACE and TLR rates were 7.6% and 2.9%, respectively, for 176 lesions treated in 145 evalua...